You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023156019
Dec 20233809
Jan 20244901
Feb 20244201
Mar 20242603
Apr 20244403
May 20241801
Jun 20243502
Jul 20242404
Aug 20242406
Sep 20242601
Oct 202430014
Nov 202488010
Dec 20242403
Jan 20253704
Feb 2025604
Mar 2025104
Apr 2025009
May 2025005
Jun 2025103
Total6690106